H.C. Wainwright lowered the firm’s price target on Genmab (GMAB) to $38 from $40 and keeps a Buy rating on the shares. Given Pfizer’s results from the MagnetisMM-5 trial, the firm sees a high likelihood that Elrexfio will be preferred over dexamethasone by physicians in relapsed or refractory multiple myeloma patients who have received at least one line of previous treatment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
- Genmab upgraded to Outperform from Neutral at BNP Paribas
- Genmab upgraded to Buy from Neutral at Goldman Sachs
- Genmab: Late‑Stage Pipeline De‑Risking and 2026 Catalysts Create Compelling 25% Upside Despite Darzalex LOE Overhang
- Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility